Evidence for risk of cardiomyopathy with hydroxychloroquine

Lupus

Volumn 21, Issue 14, 2012, Pages 1594-1596

  Sumpter, M D ^a   Tatro, L S ^a   Stoecker, W V ^a,b   Rader, R K ^b  

^a MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

^b Stoecker and Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CLOZAPINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIGOXIN; DOXORUBICIN; FLUOROURACIL; HYDROXYCHLOROQUINE; IMATINIB; INTERFERON BETA SERINE; NEVIRAPINE; NILOTINIB; ONDANSETRON; PAMIDRONIC ACID; PROPOFOL; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RITUXIMAB; ROSIGLITAZONE; TRASTUZUMAB;

CARDIOMYOPATHY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; LETTER; MEDICAL LITERATURE; OXIDATIVE STRESS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCREENING; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RISK; TIME FACTORS;

EID: 84869465715     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312462757     Document Type: Letter

References (15)

1. Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: Implications for clinical practice and research. Curr Pharm Des. 2012 ; 18: 1543-1555
2. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011 ; 127: 303-312
3. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: From malaria to autoimmunity. Clin Rev Allergy Immunol. 2012 ; 42: 145-153
4. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vas Pharmacol. 2010 ; 8: 437-449
5. Schneider S, Schmitt G, Richter W. Prevalence and correlates of inflammatory arthritis in Germany: Data from the First National Health Survey. Rheumatol Int. 2006 ; 27: 29-38
6. John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009 ; 23: 71-82
7. Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad Sci. 2007 ; 1108: 24-34
8. Costedoat-Chalumeau N, Hulot J, Amoura Z, Delcourt A, Maisonobe T, Dorent R, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology. 2007 ; 107: 73-80
9. Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: A report of 2 cases and review of the literature. Semin Arthritis Rheum. 2004 ; 33: 336-351
10. Cotroneo J, Sleik KM, Rodriguez ER, Klein AL. Hydroxychloroquine-induced restrictive cardiomyopathy. Eur J Echocardiography. 2007 ; 8: 247-251
11. Newton-Cheh C, Lin AE, Baggish AL, Wang H. Case records of the Massachusetts General Hospital. Case 11-2011: A 47-year-old man with systemic lupus erythematosus and heart failure. N Engl J Med. 2011 ; 364: 1450-1460
12. U.S. Food and Drug Administration. Adverse Events Reporting System, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/ucm070093.htm (2010, accessed July 2012).
13. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001 ; 10: 483-486
14. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007 ; 167: 1752-1759
15. Figueredo VM. Chemical cardiomyopathies: The negative effects of medications and nonprescribed drugs on the heart. Am J Med. 2011 ; 124: 480-488